LEXARIA BIOS.CORP.DL-,001 Aktie

Lexaria Bioscience has confirmed that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company received a confirmation letter from Nasdaq’s Hearings Adviser, which led to the cancellation of the scheduled hearing. The stock remains listed and traded on the Nasdaq Capital Market; the information comes from the letter filed with the SEC on Form 8-K. » Más en de.investing.com

Lexaria Bioscience will effect a 1-for-15 reverse split on August 3, 2026, to reduce outstanding shares from 24,787,446 to 1,652,518 and meet the Nasdaq Capital Market’s $1.00 per share minimum listing requirement. The number of authorized shares will be reduced to 14,666,667, fractional shares will be rounded up, and convertible securities and exercise prices will be adjusted accordingly. The company may request a hearing with Nasdaq if needed but expects to regain compliance with the minimum price rule by mid‑August; trading will continue under the ticker LEXX with a new CUSIP after the split. » Más en de.investing.com

At the BIO conference Lexaria held talks with potential pharma partners ranging from small technology firms to large corporations, with most discussions focused on the GLP-1 sector. Management reports weekly meetings and notes an industry focus on drug safety and side-effect profiles. There is renewed interest in the DehydraTECH technology outside of GLP-1, for example in CBD and nicotine applications; no concrete timelines or deal close rates were provided. » Más en de.investing.com